Moderna receives FDA fast track designation for propionic acidemia program (mRNA-3927)


22 October 2019 - mRNA-3927 is Moderna’s second rare disease program to receive fast track designation.

Moderna today announced that the U.S. FDA has granted fast track designation for mRNA-3927, its investigational mRNA therapeutic for propionic acidaemia. 

The Company announced the open IND for mRNA-3927 on 30 September 2019.

Read Moderna press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

US , Gene therapy , Fast track